# A Study to Learn More About How Safe Darolutamide is Under Real-world Conditions in Participants With Metastatic Hormone-Sensitive Prostate Cancer

> **NCT06010914** · — · ACTIVE_NOT_RECRUITING · sponsor: **Bayer** · enrollment: 100 (estimated)

## Conditions studied

- Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

## Interventions

- **OTHER:** No Intervention

## Key facts

- **NCT ID:** NCT06010914
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-10-09
- **Primary completion:** 2026-07-31
- **Final completion:** 2027-01-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06010914

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06010914, "A Study to Learn More About How Safe Darolutamide is Under Real-world Conditions in Participants With Metastatic Hormone-Sensitive Prostate Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06010914. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*